All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $29.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 01, 2020
Details:
The final closing of the Series B financing will support the advancement of an innovative fermentation production platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT013, and a pipeline of indication-specific candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OSE-127
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: $21.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 17, 2020
Details:
In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Symbiosis Pharmaceutical Services LTD
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 05, 2020
Details:
The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.